Gastroesophageal reflux disease is a disorder in which gastric contents recurrently reflux into the esophagus, causing troublesome symptoms and/or complications.
It is produced by various mechanisms such as frequent occurrence of transient relaxation of the lower esophageal sphincter or pressure abnormalities in the lower esophageal sphincter (which can be caused by hormonal and neural mediators, food, drugs and patient lifestyle).
Typical symptoms are acid regurgitation and heartburn.
Regurgitation is the perception of flow of refluxed gastric contents into the mouth or hypopharynx.
Heartburn is defined as burning sensation in the retrosternal region.
Gastric bypass leads to a rapid reduction in reflux symptoms in severely obese patients with gastro-oesophageal reflux disease (GERD), with the effect remaining stable for up to 10 years after the operation, according to a study. However, about half of the patients who receive the surgery may require continuous antireflux medication.
Duodenal eosinophilia carries up to a sixfold increased risk of developing gastro-oesophageal reflux disease (GERD) over 10 years in individuals with functional dyspepsia (FD) and postprandial distress syndrome (PDS), a study has found.
The novel potassium‐competitive acid blocker tegoprazan at either 50 or 100 mg is noninferior to esomeprazole, a proton pump inhibitor, in the treatment of erosive oesophagitis, with similar healing rates and adverse event incidences, according to the results of a phase III trial conducted in South Korea.
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
Gastro-oesophageal reflux disease (GERD) contributes to an increased risk of subsequent lacrimal drainage obstruction, and this association is evident among men and patients aged 40–59 years old, according to a study.
The Reflux Improvement and Monitoring (TRIM) programme for the management of patients with obesity and gastroesophageal reflux disease (GERD) appears to produce improvements in patient-reported symptom severity, quality of life and weight, a study reports.
Taking proton pump inhibitors (PPIs) is not associated with a higher risk of developing dementia or Alzheimer's disease (AD) among elderly people, even with high cumulative exposure or long duration of use compared with nonuse, a new study suggests.
Being diagnosed or treated for gastro-oesophageal reflux disease (GORD) has little impact on the survival outcomes of patients with idiopathic pulmonary fibrosis (IPF), according to a study presented as a poster at APSR 2017.
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
The combination of metformin, nystatin, linagliptin, rivaroxaban and a high-protein diet is the main cause of nasoenteral tube obstruction, with corresponding odds ratios of 2.0, 3.1, 4.3, 2.4 and 1.9, according to a recent study.